{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/prescribing-information/ondansetron/","result":{"pageContext":{"chapter":{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron","depth":2,"htmlHeader":"<!-- begin field 3982b3e0-f29c-4101-901d-9fd70f911d73 --><h2>Ondansetron</h2><!-- end field 3982b3e0-f29c-4101-901d-9fd70f911d73 -->","summary":"","htmlStringContent":"<!-- begin item e5d287e1-16c2-4f63-8272-190a5476aaf3 --><!-- end item e5d287e1-16c2-4f63-8272-190a5476aaf3 -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2f85b111-4cce-545b-b52b-58d48318dc8b","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field a11da045-b61d-445e-9a46-a77400a8bc3e --><h3>What dosage of ondansetron should I prescribe?</h3><!-- end field a11da045-b61d-445e-9a46-a77400a8bc3e -->","summary":"","htmlStringContent":"<!-- begin item 5f7a0c5b-8396-4aab-8fab-a77400a8b9c7 --><!-- begin field 677f8450-a98b-4a18-914d-a77400a8bc3e --><ul><li>For adults 18 years of age and older, prescribe oral ondansetron up to 8 mg twice a day for a maximum of 5 days.<ul><li>Note that the dose is based on that used for chemotherapy, so is for guidance only. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">UKMi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 677f8450-a98b-4a18-914d-a77400a8bc3e --><!-- end item 5f7a0c5b-8396-4aab-8fab-a77400a8b9c7 -->","subChapters":[]},{"id":"290a65da-52c7-5696-bd27-9e0c1ef18fba","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1b4c1725-697e-49ca-ba97-a77400a8ec94 --><h3>What are the adverse effects of ondansetron?</h3><!-- end field 1b4c1725-697e-49ca-ba97-a77400a8ec94 -->","summary":"","htmlStringContent":"<!-- begin item 54e2fc89-ac37-4ec5-a48c-a77400a8ea61 --><!-- begin field deb5fdc9-5496-4801-bb56-a77400a8ec94 --><ul><li>The most common adverse effects of ondansetron include constipation, headache, and flushing.</li><li>Other less common adverse effects include hiccups, hypotension, bradycardia, chest pain, arrhythmias, movement disorders, abnormal liver function tests, and seizures.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field deb5fdc9-5496-4801-bb56-a77400a8ec94 --><!-- end item 54e2fc89-ac37-4ec5-a48c-a77400a8ea61 -->","subChapters":[]},{"id":"fc70ba83-9b49-591e-95cf-21eb020be8bc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field d2b6df71-b257-45b5-8e90-a77400a8d120 --><h3>What are the contraindications and cautions when prescribing ondansetron?</h3><!-- end field d2b6df71-b257-45b5-8e90-a77400a8d120 -->","summary":"","htmlStringContent":"<!-- begin item 6fd2ddba-e546-4dc4-a1d6-a77400a8cf0f --><!-- begin field 0a9ffc09-34a8-488c-b314-a77400a8d120 --><ul><li>Ondansetron is contraindicated for people with:<ul><li>Congenital long QT syndrome.</li><li>Hereditary problems of galactose intolerance, Lapp lactase-deficiency or glucose-galactose malabsorption.</li></ul></li><li>Prescribe ondansetron with caution to:<ul><li>People who have or may develop prolongation of the QT interval (for example electrolyte disturbances and use of drugs that prolong the QT interval) — transient ECG changes, including QT interval prolongation and cases of Torsade de Pointes, have been reported in people taking ondansetron.</li><li>People with moderate or severe hepatic impairment — do not exceed a daily dose of 8 mg.</li><li>People with signs of subacute intestinal obstruction — ondansetron increases large bowel transit time.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 0a9ffc09-34a8-488c-b314-a77400a8d120 --><!-- end item 6fd2ddba-e546-4dc4-a1d6-a77400a8cf0f -->","subChapters":[]},{"id":"a8c6d368-3127-5a13-bf07-0dc50d103a6f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b25b6780-1c54-4266-b4a6-a77400a907cf --><h3>What drug interactions occur with ondansetron?</h3><!-- end field b25b6780-1c54-4266-b4a6-a77400a907cf -->","summary":"","htmlStringContent":"<!-- begin item 536daec9-86aa-489e-91e0-a77400a90544 --><!-- begin field ee7d5a15-ec39-4d8c-92ed-a77400a907cf --><ul><li>Drug interactions with ondansetron include:<ul><li>Drugs that prolong the QT interval or cause electrolyte abnormalities — these drugs may exacerbate the QT prolonging effect of ondansetron. Use with caution in combination with ondansetron.</li><li>Apomorphine — when combined with ondansetron, profound hypotension and loss of consciousness have been reported. Avoid concomitant use.</li><li>Selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) — serotonin syndrome (altered mental state, autonomic instability and neuromuscular abnormalities) has been reported when these drugs have been used in combination with ondansetron. </li><li>Cardiotoxic drugs (for example erythromycin, ketoconazole, amiodarone, and atenolol) — the risk of arrhythmias is increased. </li><li>Potent inducers of CYP3A4 (for example carbamazepine, phenytoin, and rifampicin) — metabolism and clearance of ondansetron is increased, reducing its blood levels.</li><li>Tramadol — the analgesic effect may be reduced by ondansetron. Monitor the analgesic response and adjust the tramadol dose accordingly. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field ee7d5a15-ec39-4d8c-92ed-a77400a907cf --><!-- end item 536daec9-86aa-489e-91e0-a77400a90544 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}